Compare Amgen, Inc. (AMGN) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Procter & Gamble Co — how do they compare? Amgen, Inc. trades at $413.07 (market cap $225.71B), while Procter & Gamble Co trades at $145.14 (market cap $340.39B). The key difference: Procter & Gamble Co is the larger of the two by market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| AMGN | PG | |
|---|---|---|
Market Cap | $225.71B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $167.18 |
52-Week Low | $271.18 | $138.10 |
Enterprise Value | $269.02B | $366.23B |
Dividend Yield | 2.42% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
Procter & Gamble (PG) trades at $146.38, up 0.42% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.90. Revenue reached $84.28B in 2025, with a net income margin of 18.44% and robust cash flow from operations of $17.82B. Analyst consensus is bullish with a $161.20 price target, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
The outlook for PG is positive due to steady earnings growth and dividend reliability, but risks include premium valuation concerns and soft demand headwinds. Investors may find opportunity in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
